Navigation Links
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
Date:8/11/2009

nd reducing pain in the early postoperative period," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "We are moving ahead with additional studies to determine optimal dosing of OMS302's mydriatic and anti-inflammatory agents."

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery((TM)) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery((TM)) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... SAN DIEGO , Aug. 27, 2015 ... second annual meeting of the Japan Society of HTLV-1, ... Science Institute Auditorium. The purpose of the Society is ... well as the development of medical technology and research ... health and welfare. "HUYA is proud to ...
(Date:8/27/2015)... , Aug. 27, 2015 In ... by FedEx, UPS and The US Postal Service ... specimens classified as ,select agents, by the CDC, ... of handling these sensitive shipments. Marken ... transportation regulations, trained and certified personnel to ensure ...
(Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
(Date:8/26/2015)... -- Intrexon Corporation (NYSE: XON ), a leader ... previously announced public offering of common stock, including the ... to purchase an additional 731,707 shares of common stock ...  The exercise of the underwriters, option brought the total ... to 5,609,756 shares and increased the total gross proceeds ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... Kuros Biosurgery AG, a biotechnology company focused ... for trauma, wound and spinal indications,announced today the ... Patent Office. This now allowed patent,application is a ... patents designed to protect Kuros’ synthetic biomaterial,(matrix) technologies ...
... (June 17, 2011)--A team of researchers has proposed a way ... to control the flow of electrons with a laser "on-off ... It,s a layer of carbon atoms only one-atom thick, but ... well and heat better than any other known material. It ...
... Calif., June 17, 2011 Pharmacyclics, Inc. (Nasdaq: ... into stock purchase agreements with various institutional investors and ... its common stock in a registered direct offering at ... 2011.  Gross proceeds of the offering, before deducting expenses, ...
Cached Biology Technology:Kuros Announces Allowance of European Patent for Synthetic Biomaterials 2Kuros Announces Allowance of European Patent for Synthetic Biomaterials 3Graphene may gain an 'on-off switch,' adding semiconductor to long list of material's achievements 2Pharmacyclics Announces Results of Registered Direct Offering 2Pharmacyclics Announces Results of Registered Direct Offering 3
(Date:8/17/2015)... Conn. , Aug. 17, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... its new sales campaign for Q4 2015. The new ... marketing team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ... Marketing Group is a leader in retail driven marketing ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2
... Dec. 20, 2012 UT Southwestern Medical Center ... the heart,s ability to regenerate, a critical step toward ... attack. Cardiologists and molecular biologists at UT Southwestern, ... regenerates, found that microRNAs tiny strands that regulate ...
... easiest and fastest way to test for harmful Escherichia ... in Frontiers in Microbiology on the 20th of December, she ... to discover specific gene targets that indicate the presence of ... this PCR system are rapid, sensitive, and reliable. ...
... may be your first choice for assistance with most ... researchers at the Johns Hopkins Bloomberg School of Public ... the best health care professionals to give weight related ... causes of and solutions to obesity care and identified ...
Cached Biology News:Research pinpoints key gene for regenerating cells after heart attack 2USDA explores using novel genetic labs for faster detection of E. coli 2Physicians admit feeling under qualified and lacking necessary education to treat obesity 2
The large Dodeca stainer shaking rack holds the staining trays in the large Dodeca stainer....
...
...
... Quansys Biosciences Q-Plex Array is a new ... human, mouse, and rat research. The Q-Plex ... ELISA-based test where 4 distinct capture antibodies ... a 96-well plate in a defined array. ...
Biology Products: